Get the Stockscreener App
464.95
0.98%
4.49
After Hours:
466.02
1.07
+0.23%
Alnylam Pharmaceuticals Inc stock is traded at $464.95, with a volume of 1.50M.
It is up +0.98% in the last 24 hours and down -0.20% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$460.46
Open:
$456.13
24h Volume:
1.50M
Relative Volume:
1.31
Market Cap:
$60.95B
Revenue:
$2.46B
Net Income/Loss:
$-319.09M
P/E Ratio:
-188.48
EPS:
-2.4669
Net Cash Flow:
$-52.09M
1W Performance:
+2.87%
1M Performance:
-0.20%
6M Performance:
+95.55%
1Y Performance:
+63.53%
1-Day Range:
$453.82
$473.65
1-Week Range:
$448.83
$473.65
52-Week Range:
$205.87
$484.21
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Has Alnylam Pharmaceuticals Inc. found a price floorMarket Risk Summary & Verified Swing Trading Watchlist - newser.com
JP Morgan Lowers Price Target for ALNY, Maintains Overweight Rat - GuruFocus
Custom watchlist performance reports with Alnylam Pharmaceuticals Inc.2025 Analyst Calls & Free Real-Time Market Sentiment Alerts - newser.com
What earnings revisions data tells us about Alnylam Pharmaceuticals Inc.Weekly Stock Report & Fast Moving Trade Plans - newser.com
Alnylam Pharma Secures $500M Credit Agreement - MSN
Vontobel Holding Ltd. Has $951,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Callan Family Office LLC Raises Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
What to do if you’re stuck in Alnylam Pharmaceuticals Inc.2025 Technical Overview & High Accuracy Trade Alerts - newser.com
Sivik Global Healthcare LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Aberdeen Group plc Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. stock ready for breakoutOil Prices & Weekly Top Gainers Trade List - newser.com
Alnylam Pharmaceuticals (ALNY): Valuation Snapshot Following New Phase 3 Data and Pipeline Progress - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright Reaffirms Their Buy Rating on Alnylam Pharma (ALNY) - The Globe and Mail
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive for dividend growthJuly 2025 Catalysts & High Accuracy Swing Trade Signals - newser.com
ALNY: HC Wainwright & Co. Reiterates Buy Rating with $570 Price Target | ALNY Stock News - GuruFocus
Is Alnylam Pharmaceuticals Inc. stock ready for a breakoutJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Using AI based signals to follow Alnylam Pharmaceuticals Inc.Trade Volume Summary & High Conviction Buy Zone Alerts - newser.com
What drives Alnylam Pharmaceuticals Inc stock priceGlobal Trade Effects & Access Risk Ratings for Every Stock - earlytimes.in
KLP Kapitalforvaltning AS Has $16.01 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Shell Asset Management Co. Purchases 1,602 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Mirae Asset Global Investments Co. Ltd. Has $1.56 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Weiss Ratings Reaffirms "Sell (D-)" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam’s AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data - MSN
Amyloidosis Clinical Market Outlook 2024-2034: Expanding Diagnostic Capabilities - openPR.com
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know - Benzinga
Did Amvuttra’s Phase 3 Update and ZENITH Trial Milestone Just Shift Alnylam’s (ALNY) Investment Narrative? - simplywall.st
Alnylam Pharmaceuticals (ALNY) Gets Target Price Boost from Morg - GuruFocus
Morgan Stanley Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $475.00 - MarketBeat
Stifel Raises Price Target for ALNY; Maintains 'Buy' Rating | AL - GuruFocus
Smart tools for monitoring Alnylam Pharmaceuticals Inc.’s price action2025 Bull vs Bear & Short-Term Trading Alerts - newser.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $495.00 Price Target at Stifel Nicolaus - MarketBeat
Morgan Stanley Raises Price Target on Alnylam Pharmaceuticals to $475 From $405, Keeps Equalweight Rating - MarketScreener
Is Alnylam Pharmaceuticals Inc. (DUL) stock a top hedge fund pickWeekly Investment Recap & Smart Money Movement Tracker - newser.com
News impact scoring models applied to Alnylam Pharmaceuticals Inc.Forecast Cut & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Alnylam Pharmaceuticals Inc a good long term investmentStraddle and Strangle Trades & Superior Wealth Growth - earlytimes.in
Is Alnylam Pharmaceuticals Inc DUL a good long term investmentGlobal Trade Effects & Build Wealth Brick by Brick With Us - earlytimes.in
Will Alnylam Pharmaceuticals Inc. (DUL) stock announce special dividendWeekly Loss Report & Accurate Intraday Trading Signals - newser.com
What indicators show strength in Alnylam Pharmaceuticals Inc.Quarterly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After ZENITH Phase 3 Trial Launch and HELIOS-B Data Reveal - simplywall.st
Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Set To Breakeven - Yahoo Finance
AMF Tjanstepension AB Makes New $10.61 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Robeco Institutional Asset Management B.V. Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Strong-Buy at Wall Street Zen - Defense World
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 2,937 Shares of Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Sells $4,034,094.20 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,364,372.56 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,727,283.05 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,405 Shares - MarketBeat
Alnylam Pharmaceuticals says on Sept 30, entered into credit agreement with Bank of AmericaSEC filing - MarketScreener
With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs? - PharmaVoice
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Oct 02 '25 |
Sale |
452.05 |
8,924 |
4,034,085 |
65,409 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Oct 02 '25 |
Sale |
452.05 |
1,405 |
635,126 |
27,438 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Oct 02 '25 |
Sale |
452.05 |
2,441 |
1,103,451 |
25,231 |
| Garg Pushkal | EVP Chief R&D |
Oct 03 '25 |
Sale |
451.48 |
3,022 |
1,364,387 |
20,221 |
| Garg Pushkal | EVP Chief R&D |
Oct 02 '25 |
Sale |
452.05 |
2,937 |
1,327,675 |
23,243 |
1.22%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):